Genzyme announced that it has restructured its collaboration with New Jersey-based PTC Therapeutics on an investigational drug.
Under the original collaboration, PTC held commercial rights in the United States and Canada for ataluren, a protein restoration therapy for genetic disorders caused by nonsense genetic mutations, while Genzyme held rights in all other countries.
Under the new agreement, PTC regains worldwide rights while Genzyme retains an option to commercialize the drug in indications other than Duchenne/Becker muscular dystrophy outside the United States and Canada. Duchenne/Becker muscular dystrophy is the most common form of the disease found in children.
Genzyme, said in a statement that the change came after a portfolio assessment and will allow the company to focus on other area while retaining an option to reengage in the collaboration.
